
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title xml:lang="srp">Uticaj signalnog puta IL-33/ST2 na razvoj nekroze kod karcinoma dojke</dc:title>
  <dc:creator>Milosavljević,  Miloš Z., 1977-</dc:creator>
  <dc:description xml:lang="srp">Interleukin-33 (IL-33)/IL-33 receptor (IL-33R, IL-RL1, ST2) signalni put promoviše
rast tumora i razvoj metastaza inhibicijom antitumorskog imunskog odgovora. IL-33 je protein sa anti- i proinflamatornom ulogom koji funkcioniše kao transkripcioni
faktor i klasičan citokin sa ulogom alarmina. Nekrotične ćelije sekretuju
imunoregulatorne citokina uključujući IL-33 koji je član IL-1 familije citokina.
Prethodne studije sugerišu da IL-33 promoviše ekspresiju i oslobađanje vaskularnog
endotelnog faktora rasta (VEGF) u mastocitima i ukazuju na njegovu proangiogenu ulogu
aktivacijom endotelnih ćelija preko IL-33R. Međutim, značaj aktivacije IL-33/IL-33R
signalnog puta u angiogenezi i tumorskoj nekrozi nije u potpunosti jasna.
Cilj naše studije je bio da se ispita uloga signalnog puta IL-33/IL-33R u tumorskoj
nekrozi i angiogenezi karcinoma dojke.
Delecija gena za IL-33R u BALB/c miševa pojačava tumorsku nekrozu u isporava rast
tumora u eksperimentalnom modelu 4T1 karcinoma dojke što je povezano sa smanjenom
ekspresijom vaskularnog endotelnog faktora rasta i IL-33 u ćelijama tumora dojke.
Ekspresija IL-33 u ćelijama karcinoma dojke raste tokom vremena u IL-33R+/+ ali ne i u
IL-33R-/-. Rezultat ukazuje na mehanizam pozitivne povratne sprege IL-33/IL-33R osovine.
Analizirali smo ekspresije IL-33. IL-33R, i VEGF.a, kao i mikrovaskularnu gustinu
(MVD) u tumorima 40 pacijenkinja sa karcinomom dojke sa prisutnom ili odsutnom
nekrozom u tkivu tumora. Detektovali smo značajno veću ekspresiju IL-33. IL-33R i
VEGF-a u tkivu karcinoma dojke bez detektabilne nekroze. Ekspresije IL-33 i IL-33R
koreliraju sa ekspresijom VEGF-a u tumorskim ćelijama. Takođe, ekspresija VEGF je
bila u pozitivnoj korelaciji sa MVD u perinekrotičnom rubu tumora.
IL-33 poput IL-1β pokauje proangiogenu ulogu i kontroliše produkciju VEGF-a. IL-1β
pojačava ekspresiju VEGF-a i njegovih receptora na endotelnim ćelijama a zajedno sa
VEGF-om promoviše tumorsku angiogenezu. Kao i IL-1, IL-33 aktivira IL-1R3 (IL-1RAcP)
ukazujuć da inhibicija ovog protein primenom anti-IL-1R3 antitela inhibira
angiogenezu tumora i pojačava tumorsku nekrozu u tkivu carcinoma dojke usled gubitka
vaskularne podpore. Na osnovu ovih rezultata smatramo da IL-33 oslobođen iz
nekrotičnih ćelija facilitira ekspresiju VEGF-a u okolnim tumorskim ćelijama
promovišući angiogenezu što je potvrđeno većom MVD u perinekrotičnoj zoni humanog
carcinoma dojke. Naši rezultati ukazuju da IL-33/IL-33R signalni put igra važnu ulogu
u rastu tumora pojačavanjem ekspresije proangiogenog VEGF-a i inhibicijom tumorske
nekroze. U dodatku na ranija istraživanja, naši rezultati ukazuju na suprotnu ulogu
intracelularnog i sekretovanog IL-33. Naša studija pokazuje dodatni mehanizam kojim
IL-33/IL-33R osovina učestvuje u karcinogenezi i daje racionalno objašnjenje za
potencijalnu blokadu IL-33 kao terapijskog modaliteta u lečenju humanog karcinoma
dojke.</dc:description>
  <dc:description xml:lang="eng">Interleukin-33 (IL-33)/IL-33 receptor (IL-33R, IL-RL1, ST2) signaling pathway promotes
mammary cancer growth and metastasis by inhibiting anti-tumor immunity. IL-33 is dual
function protein with roles as a nuclear factor and a classical cytokine and functions as a
prototypic „alarmin”. Necrotic cells release immunoregulatory cytokines, including IL-33, a
member of the IL-1 family of cytokines. Previous studies suggest that IL-33 directly facilitated
vascular endothelial growth factor (VEGF) expression and secretion in primed mast and showed
proangiogenic role of IL-33 by inducing endothelial proangiogenic activity via IL-33R
expressed on endothelial cells.However, the role of IL-33/IL-33R axis in neoangiogenesis and
tumor necrosis is not elucidated.
Therefore, the aim of this study was to investigate the role of IL-33/IL-33R axis in mammary
tumor necrosis and angiogenesis.
Deletion of IL-33R gene in BALB/c mice enhanced tumor necrosis and attenuated tumor growth
in 4T1 breast cancer model, which was associated with markedly decreased expression of VEGF
and IL-33 in mammary tumor cells. IL-33 expression in mammary tumor cells significantly
increased over time in IL-33R+
/+ mice, but not in IL-33R-/- mice the findings that reflect positive
feedback mechanism in IL-33/IL-33R axis We next analyzed IL-33, IL-33R and VEGF
expression and microvascular density (MVD) in breast tumors from 40 female patients with
absent or present tumor necrosis. We found significantly higher expression of IL-33, IL-33R and
VEGF in breast cancer tissues with absent tumor necrosis. Both, IL-33 and IL-33R expression
correlated with VEGF expression in tumor cells. Further, VEGF expression positively correlated
with MVD in perinecrotic zone.
IL-33 is very much like IL-1 in that both IL-1β and IL-33 are proangiogenic and control the
production of VEGF. IL-1β increases expression of VEGF and its receptors on endothelial cells
and acts together with VEGF in promoting tumor mediated angiogenesis. Thus, the
neutralization of IL-1β reduced tumor growth and the tumor-induced angiogenesis. As IL-1 and
IL- 33 both use IL-1R3 (IL-1RAcP), it may be speculated that anti-IL-1R3 antibodies may
reduce angiogenesis and increase tumor necrosis in breast cancer due to loss of vascular supply.
On the basis of these observations we suggest that IL-33 released by necrotic cells may facilitate
VEGF expression on nearby tumor cells, which could lead to enhanced angiogenesis as
demonstrated by high-grade MVD in perinecrotic zone in human breast cancer tissue. Taking
together, our data indicate that IL-33/IL-33R pathway is critically involved in mammary tumor
growth by facilitating expression of pro-angiogenic VEGF in tumor cells and attenuating tumor
necrosis. Additionally, results indicate oposite functions of intracellular and secreted IL-33.
Thus, this study revealed an additional mechanism by which IL-33/IL-33R pathway may be
involved in tumorigenesis and provide rationale for blocking IL-33 as a therapeutic modality in
human breast carcinoma.</dc:description>
  <dc:description xml:lang="srp"></dc:description>
  <dc:contributor>Jovanović,  Ivan.</dc:contributor>
  <dc:contributor>Lukić,  Miodrag.</dc:contributor>
  <dc:contributor>Knežević Ušaj,  Slavica, 1957-</dc:contributor>
  <dc:contributor>Radosavljević,  Gordana, 1976-</dc:contributor>
  <dc:date>2017</dc:date>
  <dc:date>2017</dc:date>
  <dc:date>2017</dc:date>
  <dc:date>2017</dc:date>
  <dc:date>2017</dc:date>
  <dc:date>2017</dc:date>
  <dc:type xml:lang="eng">baccalaureate Dissertation</dc:type>
  <dc:format>273 lista</dc:format>
  <dc:format>6491363 bytes</dc:format>
  <dc:identifier>o:755</dc:identifier>
  <dc:identifier>ID=523723925 ; D-3013</dc:identifier>
  <dc:identifier>thesis:4630</dc:identifier>
  <dc:identifier>cobiss:523723925</dc:identifier>
  <dc:identifier>https://phaidrakg.kg.ac.rs/o:755</dc:identifier>
  <dc:source>Thesis:4630</dc:source>
  <dc:source>Cobiss:523723925</dc:source>
  <dc:language>srp</dc:language>
  <dc:rights>CC BY 2.0 AT</dc:rights>
  <dc:rights>http://creativecommons.org/licenses/by/2.0/at/</dc:rights>
</oai_dc:dc>
